Dec 20 |
Sargramostim for COVID-19: real-time meta analysis of 4 studies | |
| Meta analysis using the most serious outcome reported shows 13% [-31‑85%] higher risk, without reaching statistical significance. Currently all studies are RCTs. Currently there is limited data, with only 870 patients and only .. | ||
Nov 27 2023 |
et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofad500.351 | 279. Inhaled Sargramostim (rhu GM-CSF) Leads to Enhanced SARS-CoV-2 Virus-Specific Immune Response and Viral Clearance: Results of the Biomarker Cohort of a Randomized, Double-Blind, Placebo-Controlled Phase 2b Trial in Non-Hospitalized Patients with COVID-19 |
| 30% higher progression (p=0.5) and 27% improved viral clearance (p=0.005). RCT 600 non-hospitalized COVID-19 patients at high risk for progression showing enhanced SARS-CoV-2 viral clearance by day 14 with inhaled sargramostim (rhu GM-CSF) compared to placebo. There was no significant difference in the primary e.. | ||
Sep 20 2023 |
et al., Infectious Diseases, doi:10.1080/23744235.2023.2254380 | Short-term inhalation of sargramostim with concomitant high-dose steroids does not hasten recovery in moderate COVID-19 pneumonia: a double-blind, randomised, placebo-controlled trial |
| 12% slower improvement (p=0.1) and 10% longer hospitalization. RCT 70 hospitalized COVID-19 patients with moderate pneumonia in Japan showing no significant difference in time to clinical improvement with inhaled sargramostim (GM-CSF) vs. placebo. Concomitant corticosteroid dose was not standardized... | ||
Dec 2 2022 |
et al., Military Medicine, doi:10.1093/milmed/usac362 | Inhaled Sargramostim (Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor) for COVID-19-Associated Acute Hypoxemia: Results of the Phase 2, Randomized, Open-Label Trial (iLeukPulm) |
| 23% lower mortality (p=0.58), 27% lower ventilation (p=0.58), 56% lower need for oxygen therapy (p=0.04), and 3% longer hospitalization (p=0.86). RCT 122 hospitalized COVID-19 patients showing improved oxygenation with inhaled sargramostim (GM-CSF) treatment. There was no significant difference in intubation rate, mortality, or adverse events. | ||
Oct 13 2021 |
et al., Research Square, doi:10.21203/rs.3.rs-959220/v1 | Early treatment with inhaled GM-CSF improves oxygenation and anti-viral immunity in COVID-19 induced lung injury – a randomized clinical trial |
| 20% higher ventilation (p=0.77), 10% worse results (p=0.77), and 43% lower need for oxygen therapy (p=0.13). RCT 81 non-ventilated COVID-19 patients with hypoxemic respiratory failure showing improved oxygenation after 5 days of inhaled sargramostim (rhu-GM-CSF) compared to standard of care. More patients in the sargramostim group experienced at.. | ||
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.